Oxford BioMedica plc. (9/4/17). "Press Release: Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York". Oxford.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Oxford BioMedica plc (LSE: OXB)
	Group	Oxford BioMedica (Group)
	Organisation 2	Rodman & Renshaw Conferences LLC
	Product	Rodman & Renshaw Annual Global Investment Conference 2017 New York
	Product 2	LentiVector® technology
	Index term	Oxford BioMedica–Rodman & Renshaw: investor conference, 201709 supply service OBM presents at Rodman & Renshaw Global Investment Conference in NY
	Index term 2	Oxford BioMedica–Consilium: public relations, 201604 service existent by CSC
	Person	Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
	Person 2	Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Tuesday 12 September at 08:20 EST.

-Ends-

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000

Consilium Strategic Communications – Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700

Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900

WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321

Record changed: 2018-06-09